Show simple item record

Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b

dc.contributor.authorBadur, S
dc.contributor.authorBasaran, Gülcan
dc.contributor.authorTurkoglu, S
dc.contributor.authorOzbay, Gülşen
dc.contributor.authorTabak, F
dc.contributor.authorSenturk, H
dc.contributor.authorMert, A
dc.contributor.authorAkdogan, M
dc.date.accessioned2021-03-05T21:29:10Z
dc.date.available2021-03-05T21:29:10Z
dc.date.issued2000
dc.identifier.citationSenturk H., Mert A., Akdogan M., Tabak F., Basaran G., Turkoglu S., Ozbay G., Badur S., "Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, cilt.32, ss.575-576, 2000
dc.identifier.issn0036-5548
dc.identifier.othervv_1032021
dc.identifier.otherav_d91853e9-6d5a-4d95-932b-c2fe5454e9d6
dc.identifier.urihttp://hdl.handle.net/20.500.12627/143219
dc.description.abstractWe aimed to test the efficacy of amantadine in chronic hepatitis C (CHC) patients infected with genotype Ib. Twenty patients completed treatment with amantadine HCl, 100 mg b.i.d., for 6 months. Non-sustained biochemical improvement was observed without loss of HCV-RNA, We conclude that amantadine monotherapy is not effective in CHC.
dc.language.isoeng
dc.subjectİmmünoloji
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectYaşam Bilimleri (LIFE)
dc.titleAmantadine monotherapy of chronic hepatitis C patients infected with genotype 1b
dc.typeMakale
dc.relation.journalSCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
dc.contributor.department, ,
dc.identifier.volume32
dc.identifier.issue5
dc.identifier.startpage575
dc.identifier.endpage576
dc.contributor.firstauthorID41124


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record